The NIH sponsored study will examine maintenance of hemoglobin, iron parameters, need for intravenous iron and oxidative stress markers in patients receiving soluble ferric pyrophosphate (SFP) via dialysate versus patients receiving conventional iron-free dialysate. New data from this important study is expected to be published in late 2008.
Mordechai Nosrati, associate professor of clinical medicine at Keck-USC School of Medicine and co-principal investigator, said: “SFP in dialysate allows for the slow infusion of iron over a four-hour dialysis session and physiologically mimics how the human body normally handles and processes dietary iron, thereby potentially mitigating the side effects associated with intravenous iron such as release of free iron and excess storage of iron in the liver.”